Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025

PR Newswire

BURLINGTON, Mass., Nov. 21, 2025


	Quarter Ended								Year Ended
Dollars in millions, except per share data	September 30,			September 30,					September 30,			September 30,
	2025			2024⁽¹⁾			Change		2025			2024⁽¹⁾			Change
Revenue from Continuing Operations	$	159		$	151			6 %	$	594		$	573			4 %
Organic growth								4 %								3 %
Sample Management Solutions	$	86		$	85			2 %	$	325		$	319			2 %
Multiomics	$	73		$	66			11 %	$	269		$	255			6 %

Diluted EPS Continuing Operations	$	1.11		$	(0.04)			NM	$	0.52		$	(0.46)			NM
Diluted EPS Total	$	1.02		$	(0.14)			NM	$	(1.30)		$	(3.10)			58 %

Non-GAAP Diluted EPS Continuing Operations	$	0.21		$	0.19			8 %	$	0.51		$	0.48			8 %
Adjusted EBITDA Continuing Operations	$	21		$	16			29 %	$	66		$	46			44 %
Adjusted EBITDA Margin - Continuing Operations		13.0	%		10.7	%				11.2	%		8.0	%

(1)	Reflects revisions for an immaterial classification error among cost of revenue, research and development expenses, and selling, general and administrative expenses, and other immaterial adjustments, as further described in this release.

AZENTA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

(In thousands, except per share data)

	Three Months Ended				Year Ended
	September 30,				September 30,
	2025		2024		2025		2024
Revenue
Products	$	48,020	$	47,210	$	173,189	$	173,717
Services		111,172		103,394		420,632		399,731
Total revenue		159,192		150,604		593,821		573,448
Cost of revenue
Products		26,287		28,281		94,894		105,446
Services		60,631		53,836		228,647		213,380
Total cost of revenue		86,918		82,117		323,541		318,826
Gross profit		72,274		68,487		270,280		254,622
Operating expenses
Research and development		8,258		7,539		30,390		31,524
Selling, general and administrative		61,709		64,734		261,563		262,958
Impairment of goodwill and intangible assets		—		—		—		4,658
Restructuring charges		406		851		5,171		6,766
Total operating expenses		70,373		73,124		297,124		305,906
Operating income (loss)		1,901		(4,637)		(26,844)		(51,284)
Other income (expense)
Interest income, net		5,019		5,532		18,779		32,891
Other income (expense), net		(620)		(604)		922		(732)
Income (loss) from continuing operations before income taxes		6,300		291		(7,143)		(19,125)
Income tax (benefit) expense		(44,553)		2,036		(30,801)		5,241
Income (loss) from continuing operations		50,853		(1,745)		23,658		(24,366)
Loss from discontinued operations, net of tax		(3,716)		(4,894)		(83,161)		(140,531)
Net income (loss)	$	47,137	$	(6,639)	$	(59,503)	$	(164,897)
Basic net income (loss) per share:
Income (loss) from continuing operations	$	1.11	$	(0.04)	$	0.52	$	(0.46)
Loss from discontinued operations, net of tax		(0.08)		(0.10)		(1.82)		(2.64)
Net income (loss) per share	$	1.03	$	(0.14)	$	(1.30)	$	(3.10)
Diluted net income (loss) per share:
Income (loss) from continuing operations	$	1.11	$	(0.04)	$	0.52	$	(0.46)
Loss from discontinued operations, net of tax		(0.08)		(0.10)		(1.81)		(2.64)
Diluted net income (loss) per share	$	1.02	$	(0.14)	$	(1.30)	$	(3.10)
Weighted average shares used in computing net income (loss) per share:
Basic		45,833		48,079		45,743		53,175
Diluted		45,994		48,079		45,896		53,175

AZENTA, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except share and per share data)

	September 30,		September 30,
	2025		2024

Assets
Current assets
Cash and cash equivalents	$	279,783	$	280,030
Short-term marketable securities		61,137		151,162
Accounts receivable, net of allowance for expected credit losses ($4,649 and $5,349, respectively)		142,181		154,172
Inventories		74,956		71,320
Short-term restricted cash		2,359		2,069
Refundable income taxes		9,728		23,866
Prepaid expenses and other current assets		64,660		51,360
Current assets held for sale		74,830		99,052
Total current assets		709,634		833,031
Property, plant and equipment, net		153,954		155,622
Long-term marketable securities		201,585		49,454
Long-term deferred tax assets		726		837
Operating lease right-of-use assets		54,048		60,406
Goodwill		702,395		691,409
Intangible assets, net		101,814		125,042
Long term income taxes receivable		45,600		—
Other assets		6,115		10,670
Noncurrent assets held for sale		80,983		173,794
Total assets	$	2,056,854	$	2,100,265
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	37,722	$	33,344
Deferred revenue		32,569		30,493
Derivative liability		33,420		1,915
Accrued warranty and retrofit costs		4,713		5,213
Accrued compensation and benefits		35,799		29,216
Accrued customer deposits		26,499		22,324
Accrued income taxes payable		9,416		9,085
Accrued expenses and other current liabilities		30,268		44,443
Current liabilities held for sale		29,563		30,050
Total current liabilities		239,969		206,083
Long-term deferred tax liabilities		19,046		18,184
Long-term operating lease liabilities		51,244		56,683
Other long-term liabilities		10,140		9,272
Noncurrent liabilities held for sale		13,209		42,196
Total liabilities		333,608		332,418

Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding		—		—
and 45,570,084 shares outstanding at September 30, 2024		594		590
Additional paid-in capital		529,605		505,958
Accumulated other comprehensive loss		(22,213)		(13,464)
Treasury stock, at cost - 13,461,869 shares at September 30, 2025 and September 30, 2024		(200,956)		(200,956)
Retained earnings		1,416,216		1,475,719
Total stockholders' equity		1,723,246		1,767,847
Total liabilities and stockholders' equity	$	2,056,854	$	2,100,265

AZENTA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)

	Year Ended
	September 30,
	2025		2024
Cash flows from operating activities
Net loss	$	(59,503)	$	(164,897)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		61,209		90,744
Impairment of goodwill and intangible assets		—		115,975
Loss on assets held for sale		97,139		—
Property, plant and equipment and other asset write-offs		3,478		4,430
Inventory write-downs		—		3,290
Other non-cash charges related to restructuring and transformation		—		4,317
Stock-based compensation		20,881		14,467
Amortization and accretion on marketable securities		(1,578)		(6,032)
Deferred income taxes		(27,152)		(16,072)
Loss on disposals of property, plant and equipment		711		296
Changes in operating assets and liabilities:
Accounts receivable		21,039		(11,589)
Inventories		(3,966)		15,896
Accounts payable		1,037		9,196
Deferred revenue		1,641		(3,558)
Accrued warranty and retrofit costs		(435)		(684)
Accrued compensation and tax withholdings		6,607		(2,754)
Long term income taxes receivable		(45,600)		—
Other assets and liabilities		(3,327)		(3,282)
Net cash provided by operating activities		72,181		49,743
Cash flows from investing activities
Purchases of property, plant and equipment		(33,857)		(37,392)
Purchases of marketable securities and other investments		(451,409)		(405,575)
Sales and maturities of marketable securities		389,452		666,230
Proceeds from other investment		2,130		—
Net investment hedge settlement		3,223		1,476
Net cash (used in) provided by investing activities		(90,461)		224,739
Cash flows from financing activities
Proceeds from issuance of common stock		2,770		3,279
Payments of finance leases		(985)		(783)
Share repurchases		—		(661,703)
Excise tax payment for settled share repurchases		(11,376)		—
Net cash used in financing activities		(9,591)		(659,207)
Effects of exchange rate changes on cash and cash equivalents		3,566		21,670
Net decrease in cash, cash equivalents and restricted cash		(24,305)		(363,055)
Cash, cash equivalents and restricted cash, beginning of period		320,990		684,045
Cash, cash equivalents and restricted cash, end of period	$	296,685	$	320,990
Supplemental disclosures:
Cash paid for income taxes, net	$	6,568		2,704
Purchases of property, plant and equipment included in accounts payable and accrued expenses		4,693		2,767
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents of continuing operations	$	279,783	$	280,030
Cash included in current assets held for sale		13,206		30,899
Short-term restricted cash included in prepaid expenses and other current assets		2,359		2,069
Long-term restricted cash included in other assets		1,337		7,992
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	296,685	$	320,990

	Quarter Ended
	September 30, 2025					June 30, 2025^(*)					September 30, 2024^(*)
				per diluted					per diluted					per diluted
Dollars in thousands, except per share data	$			share		$			share		$			share
Net income (loss) from continuing operations	$	50,853		$	1.11	$	(331)		$	(0.01)	$	(1,745)		$	(0.04)
Adjustments:
Amortization of completed technology		2,088			0.05		2,068			0.05		2,096			0.04
Amortization of other intangible assets		3,977			0.09		4,123			0.09		4,842			0.10
Transformation costs⁽¹⁾		634			0.01		1,542			0.03		4,568			0.10
Restructuring charges		406			0.01		754			0.02		851			0.02
Merger and acquisition costs and costs related to share repurchase⁽²⁾		87			0.00		58			0.00		52			0.00
Tax adjustments(3)		(46,160)			(1.00)		—			—		259			0.01
Tax effect of adjustments		(2,246)			(0.05)		(534)			(0.01)		(1,576)			(0.03)
Other Adjustments		—			—		38			0.00		—			—
Non-GAAP adjusted net income from continuing operations	$	9,639		$	0.21	$	7,718		$	0.17	$	9,347		$	0.19
Stock-based compensation, pre-tax		3,901			0.08		3,045			0.07		1,649			0.03
Tax rate		17	%		—		17	%		—		14	%		—
Stock-based compensation, net of tax		3,238			0.07		2,536			0.06		1,418			0.03
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations	$	12,877		$	0.28	$	10,254		$	0.22	$	10,765		$	0.22

Shares used in computing non-GAAP diluted net income per share					45,994					45,780					48,079

	Year Ended
	September 30, 2025					September 30, 2024^(*)
				per diluted					per diluted
Dollars in thousands, except per share data	$			share		$			share
Net income (loss) from continuing operations	$	23,658		$	0.52	$	(24,366)		$	(0.46)
Adjustments:
Amortization of completed technology		7,965			0.17		8,066			0.15
Amortization of other intangible assets		16,475			0.36		20,496			0.39
Transformation costs⁽¹⁾		10,405			0.23		9,879			0.19
Restructuring charges		5,171			0.11		6,766			0.13
Impairment of goodwill and intangible assets		—			—		4,658			0.09
Merger and acquisition costs and costs related to share repurchase⁽²⁾		2,403			0.05		4,874			0.09
Investment income⁽³⁾		(2,130)			(0.05)		—			—
Tax adjustments⁽⁴⁾		(38,860)			(0.85)		3,638			0.07
Tax effect of adjustments		(1,675)			(0.04)		(8,668)			(0.16)
Other special charges		38			0.00		—			—
Non-GAAP adjusted net income from continuing operations	$	23,450		$	0.51	$	25,343		$	0.48
Stock-based compensation, pre-tax		19,849			0.43		13,750			0.26
Tax rate		17	%		—		14	%		—
Stock-based compensation, net of tax		16,475			0.36		11,825			0.22
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations	$	39,925		$	0.87	$	37,168		$	0.70

Shares used in computing non-GAAP diluted net income per share		—			45,896		—			53,175


(*)	See footnote (1) on Page 1.
⁽¹⁾	Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 cost reduction plan, and primarily relate to one time asset write-downs associated with changes in technology, one time inventory write-downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.
⁽²⁾	Includes expenses related to governance-related matters.
⁽³⁾	The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature.
(4)	Tax adjustments during all periods include adjustments to tax benefits related to stock-based compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. In the fourth quarter of fiscal year 2025, tax adjustments include a one-time $45.6 million benefit related to a worthless stock deduction on one of the Company's foreign subsidiaries, that is excluded from non-GAAP results.

	Quarter Ended						Year Ended
	September 30,		June 30,		September 30,		September 30,		September 30,
Dollars in thousands	2025		2025^(*)		2024^(*)		2025		2024^(*)
GAAP net income (loss)	$	47,137	$	(47,984)	$	(6,639)	$	(59,503)	$	(164,897)
Less: Loss from discontinued operations		(3,716)		(47,653)		(4,894)		(83,161)		(140,531)
GAAP net income (loss) from continuing operations		50,853		(331)		(1,745)		23,658		(24,366)
Adjustments:
Interest income, net		(5,019)		(4,973)		(5,532)		(18,779)		(32,891)
Income tax expense		(44,553)		2,635		2,036		(30,801)		5,241
Depreciation		8,338		8,399		7,275		32,033		29,691
Amortization of completed technology		2,088		2,068		2,096		7,965		8,066
Amortization of other intangible assets		3,977		4,123		4,842		16,475		20,496
Earnings before interest, taxes, depreciation and amortization - Continuing operations	$	15,684	$	11,921	$	8,972	$	30,551	$	6,237

	Quarter Ended						Year Ended
	September 30,		June 30,		September 30,		September 30,		September 30,
Dollars in thousands	2025		2025^(*)		2024^(*)		2025		2024^(*)
Earnings before interest, taxes, depreciation and amortization - Continuing operations	$	15,684	$	11,921	$	8,972	$	30,551	$	6,237
Adjustments:
Stock-based compensation		3,901		3,045		1,649		19,849		13,750
Restructuring charges		406		754		851		5,171		6,766
Impairment of goodwill and intangible assets		—		—		—		—		4,658
Merger and acquisition costs and costs related to share repurchase⁽¹⁾		87		58		52		2,403		4,874
Transformation costs⁽²⁾		634		1,542		4,568		10,405		9,879
Investment Income⁽³⁾		—		—		—		(2,130)		—
Other adjustments		—		38		—		34		—
Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations	$	20,712	$	17,358	$	16,092	$	66,283	$	46,164


(*)	See footnote (1) on Page 1.
(1)	Includes expenses related to governance-related matters.
(2)	Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 cost reduction plan, and primarily relate to one time asset write-downs associated with changes in technology, one time inventory write-downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.
(3)	The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature.

	Quarter Ended
Dollars in thousands	September 30, 2025				June 30, 2025^(*)				September 30, 2024^(*)
GAAP gross profit	$	72,274	45.4	%	$	66,404	46.2	%	$	68,487	45.5	%
Adjustments:
Amortization of completed technology		2,088	1.3	%		2,068	1.4	%		2,096	1.4	%
Transformation costs⁽¹⁾		—	—	%		—	—	%		145	0.1	%
Other adjustments		—	—	%		25	0.0	%		—	—	%
Non-GAAP adjusted gross profit	$	74,362	46.7	%	$	68,497	47.6	%	$	70,728	47.0	%

	Year Ended
Dollars in thousands	September 30, 2025				September 30, 2024^(*)
GAAP gross profit	$	270,280	45.5	%	$	254,622	44.4	%
Adjustments:
Amortization of completed technology		7,965	1.3	%		8,066	1.4	%
Transformation costs⁽¹⁾		52	0.0	%		377	0.1	%
Other adjustment		18	0.0	%		(20)	(0.0)	%
Non-GAAP adjusted gross profit	$	278,315	46.9	%	$	263,045	45.9	%


(*)	See footnote (1) on Page 1.
⁽¹⁾	Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 cost reduction plan, and primarily relate to one time asset write-downs associated with changes in technology, one time inventory write-downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

	Sample Management Solutions												Multiomics
	Quarter Ended												Quarter Ended
	September 30,				June 30,				September 30,				September 30,				June 30,				September 30,
Dollars in thousands	2025				2025^(*)				2024^(*)				2025				2025^(*)				2024^(*)
GAAP gross profit	$	41,175	47.9	%	$	40,178	51.8	%	$	38,992	46.1	%	$	31,094	42.5	%	$	26,222	39.6	%	$	29,476	44.7	%
Adjustments:
Amortization of completed technology		1,226	1.4	%		1,208	1.6	%		1,056	1.2	%		862	1.2	%		860	1.3	%		1,040	1.6	%
Transformation costs⁽¹⁾		—	—	%		25	0.0	%		145	0.2	%		—	—			—	—			—	—
Non-GAAP adjusted gross profit	$	42,401	49.3	%	$	41,411	53.4	%	$	40,193	47.5	%	$	31,956	43.7	%	$	27,082	40.9	%	$	30,516	46.2	%

	Total Segments
	Quarter Ended
	September 30,				June 30,				September 30,
Dollars in thousands	2025				2025^(*)				2024^(*)
GAAP gross profit	$	72,274	45.4	%	$	66,400	46.2	%	$	68,487	45.5	%
Adjustments:
Amortization of completed technology		2,088	1.3	%		2,068	1.4	%		2,096	1.4	%
Transformation costs⁽¹⁾		—	—	%		25	0.0	%		145	0.1	%
Non-GAAP adjusted gross profit	$	74,362	46.7	%	$	68,493	47.6	%	$	70,728	47.0	%

	Sample Management Solutions								Multiomics
	Year Ended								Year Ended
Dollars in thousands	September 30, 2025				September 30, 2024^(*)				September 30, 2025				September 30, 2024^(*)
GAAP gross profit	$	156,645	48.3	%	$	141,447	44.4	%	$	113,635	42.2	%	$	113,175	44.5	%
Adjustments:
Amortization of completed technology		4,522	1.4	%		3,909	1.2	%		3,443	1.3	%		4,157	1.6	%
Transformation costs⁽¹⁾		52	0.0	%		377	0.1	%		—	—			—	—
Other adjustment		26	0.0	%		(10)	(0.0)	%		(8)	(0.0)	%		(10)	(0.0)	%
Non-GAAP adjusted gross profit	$	161,245	49.7	%	$	145,723	45.7	%	$	117,070	43.5	%	$	117,322	46.1	%

	Total Segments
	Year Ended
Dollars in thousands	September 30, 2025				September 30, 2024^(*)
GAAP gross profit	$	270,280	45.5	%	$	254,622	44.4	%
Adjustments:
Amortization of completed technology		7,965	1.3	%		8,066	1.4	%
Transformation costs⁽¹⁾		52	0.0	%		377	0.1	%
Other adjustment		18	0.0	%		(20)	(0.0)	%
Non-GAAP adjusted gross profit	$	278,315	46.9	%	$	263,045	45.9	%


(*)	See footnote (1) on Page 1.
⁽¹⁾	Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 cost reduction plan, and primarily relate to one time asset write-downs associated with changes in technology, one time inventory write-downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

	Sample Management Solutions						Multiomics
	Quarter Ended						Quarter Ended
	September 30,		June 30,		September 30,		September 30,		June 30,		September 30,
Dollars in thousands	2025		2025^(*)		2024^(*)		2025		2025^(*)		2024^(*)
GAAP operating income (loss)	$	8,015	$	9,323	$	7,503	$	(1,029)	$	(4,818)	$	(2,009)
Adjustments:								.				.
Amortization of completed technology		1,226		1,208		1,056		862		860		1,040
Transformation costs⁽¹⁾		(57)		168		163		—		—		—
Other adjustment		42		38		—		31		—		—
Non-GAAP adjusted operating income (loss)	$	9,226	$	10,737	$	8,722	$	(136)	$	(3,958)	$	(969)

	Total Segments						Corporate						Total
	Quarter Ended						Quarter Ended						Quarter Ended
	September 30,		June		September 30,		September 30,		June		September 30,		September 30,		June		September 30,
Dollars in thousands	2025		2025^(*)		2024^(*)		2025		2025^(*)		2024^(*)		2025		2025^(*)		2024^(*)
GAAP operating income (loss)	$	6,986	$	4,505	$	5,494	$	(5,085)	$	(6,355)	$	(10,131)	$	1,901	$	(1,850)	$	(4,637)
Adjustments:
Amortization of completed technology		2,088		2,068		2,096		—		—		—		2,088		2,068		2,096
Amortization of other intangible assets		—		—		—		3,977		4,123		4,842		3,977		4,123		4,842
Transformation costs⁽¹⁾		(57)		168		163		691		1,374		4,405		634		1,542		4,568
Restructuring charges		—		—		—		406		754		851		406		754		851
Merger and acquisition costs and costs related to share repurchase⁽²⁾		—		—		—		87		58		52		87		58		52
Other adjustment		73		38		—		(73)		—		—		—		38		—
Non-GAAP adjusted operating income (loss)	$	9,090	$	6,779	$	7,753	$	3	$	(46)	$	19	$	9,093	$	6,733	$	7,772

	Sample Management Solutions				Multiomics
	Year Ended				Year Ended
	September 30,		September 30,		September 30,		September 30,
Dollars in thousands	2025		2024^(*)		2025		2024^(*)
GAAP operating income (loss)	$	20,124	$	6,647	$	(15,414)	$	(11,893)
Adjustments:
Amortization of completed technology		4,522		3,909		3,443		4,157
Amortization of other intangible assets		—		155		—		—
Transformation costs⁽¹⁾		2,820		395		—		—
Other adjustments		84		—		34		3
Non-GAAP adjusted operating income (loss)	$	27,550	$	11,106	$	(11,937)	$	(7,733)

	Total Segments				Corporate				Total
	Year Ended				Year Ended				Year Ended
	September 30,		September 30,		September 30,		September 30,		September 30,		September 30,
Dollars in thousands	2025		2024^(*)		2025		2024^(*)		2025		2024^(*)
GAAP operating income (loss)	$	4,710	$	(5,246)	$	(31,554)	$	(46,038)	$	(26,844)	$	(51,284)
Adjustments:
Amortization of completed technology		7,965		8,066		—		—		7,965		8,066
Amortization of other intangible assets		—		155		16,475		20,341		16,475		20,496
Transformation costs⁽¹⁾		2,820		395		7,585		9,484		10,405		9,879
Restructuring charges		—		—		5,171		6,766		5,171		6,766
Impairment of goodwill and intangible assets		—		—		—		4,658		—		4,658
Merger and acquisition costs and costs related to share repurchase⁽²⁾		—		—		2,403		4,874		2,403		4,874
Other adjustments		118		3		(84)		(24)		34		(21)
Non-GAAP adjusted operating income (loss)	$	15,613	$	3,373	$	(4)	$	61	$	15,609	$	3,434


(*)	See footnote (1) on Page 1.
⁽¹⁾	Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 cost reduction plan, and primarily relate to one time asset write-downs associated with changes in technology, one time inventory write-downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.
⁽²⁾	Includes expenses related to governance-related matters.

	Sample Management Solutions							Multiomics							Azenta Total
	Quarter Ended							Quarter Ended							Quarter Ended
	September 30,		September 30,					September 30,		September 30,					September 30,		September 30,
Dollars in millions	2025		2024		Change			2025		2024		Change			2025		2024		Change
Revenue	$	86	$	85		2	%	$	73	$	66		11	%	$	159	$	151		6	%
Currency exchange rates		(1)		—		(2)	%		(1)		—		(1)	%		(2)		—		(2)	%
Organic revenue	$	85	$	85		0	%	$	72	$	66		10	%	$	157	$	151		4	%

	Sample Management Solutions							Multiomics							Azenta Total
	Year Ended							Year Ended							Year Ended
	September 30,		September 30,					September 30,		September 30,					September 30,		September 30,
Dollars in millions	2025		2024		Change			2025		2024		Change			2025		2024		Change
Revenue	$	325	$	319		2	%	$	269	$	255		6	%	$	594	$	573		4	%
Currency exchange rates		(3)		—		(1)	%		(1)		—		(0)	%		(4)		—		(1)	%
Organic revenue	$	322	$	319		1	%	$	268	$	255		5	%	$	590	$	573		3	%

/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025.BURLINGTON, Mass.Nov. 21, 2025

AzentaManagement Comments

"Fiscal 2025 was a transformative year for. We achieved 3% core revenue growth and meaningful margin expansion," said John, President and Chief Executive Officer. "We simplified our organization, made significant progress enabled by theBusiness System, and strengthened our execution, which is driving measurable improvements in quality, delivery, and productivity."

Mr. Marotta continued, "We enter fiscal 2026 in a healthier position, with a more streamlined and accountable structure, with sharper focus on the customer, and growing momentum across the business. We expect core growth between 3% and 5%, approximately 300 basis points of adjusted EBITDA margin expansion, and higher free cash flow generation." 

-Fourth Quarter Fiscal 2025 ResultsContinuing Operations

Summary of GAAP Earnings Results - Continuing Operations

Summary of Non-GAAP Earnings Results - Continuing Operations

Full Year Fiscal 2025 Results - Continuing Operations

Summary of GAAP Results - Continuing Operations

Summary of Non-GAAP Results - Continuing Operations

Cash and Liquidity as of September 30, 2025

Guidance for Full Year Fiscal 2026

During the fourth quarter of fiscal 2025, the Company identified a classification error in previously issued consolidated statements of operations. Certain costs had been incorrectly allocated among cost of revenue, research and development expenses, and selling, general and administrative expenses. As a result, cost of revenue and research and development expenses were understated and selling, general and administrative expenses were overstated by equal and offsetting amounts. The Company concluded that the error was not material, individually or in the aggregate, to any previously issued financial statements. Accordingly, the Company has corrected the error by revising the consolidated financial statements for all affected prior periods as presented herein. These revisions also reflect the correction of certain other immaterial prior-period errors that had previously been corrected on an out-of-period basis in the periods in which they were identified. Management is evaluating the impact of the classification error on the effectiveness of the Company's internal control over financial reporting. Further information regarding these revisions will be provided in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025.Revision of Previously Issued Financial Statements

Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.

Azenta management will webcast its fourth quarter and full year fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.Conference Call and Webcast

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website athttps://investors.azenta.com/events

The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.Regulation GUse of Non-GAAP financial Measures

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release."Safe Harbor Statementunder Section 21E of the Securities Exchange Act of 1934

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.About Azenta Life Sciences

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visitwww.azenta.com

AZENTA INVESTOR CONTACTS:

Yvonne Perron

ir@azenta.com

Maria Isabel Cuartas

ir@azenta.com

Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.Notes on Non-GAAP Financial Measures

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-reports-fourth-quarter-and-full-year-fiscal-2025-results-ended-september-30-2025-302623017.html

SOURCE Azenta

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basis
FY'25 reported revenue growth of 4% and 3% on an organic basis
FY'25 Adjusted EBITDA margin expansion of 310 basis points versus last year
FY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points

Revenue was $159 million, up 6% year over year. Organic revenue, which excludes the impact from foreign exchange, grew 4% year over year, mainly attributable to higher revenue in Multiomics.
Sample Management Solutions revenue was $86 million, up 2% year over year.
- Organic revenue was flat, mainly driven by lower revenue in Cryogenic Systems, offset by higher revenue in Clinical Biostores, Automated Stores, Consumables and Instruments, and Sample Storage.
Multiomics revenue was $73 million, up 11% year over year.
- Organic revenue grew 10% year over year, primarily driven by growth in Next Generation Sequencing and Gene Synthesis, partially offset by a year-over-year decline in Sanger sequencing revenue.

Operating income was $2 million. Operating margin was 1.2%, an improvement of 430 basis points year over year.
- Gross margin was 45.4%, flat year over year, reflecting continued cost discipline, operational improvements, and favorable sales mix in Sample Management Solutions, offset by higher costs and lower volumes in parts of the Multiomics segment.
- Operating expenses were $70 million, down 4% year over year, primarily driven by lower selling, general and administrative expenses, lower transformation and lower restructuring charges, partially offset by higher research and development costs.
Other income included $5 million of net interest income versus $6 million in the prior year period.
Tax adjustments include a one-time $45.6 million benefit related to a worthless stock deduction on one of the Company's foreign subsidiaries.
Diluted EPS from continuing operations was $1.11 compared to ($0.04) one year ago. Diluted EPS from discontinued operations was ($0.08). Total diluted EPS was $1.02, compared to ($0.14) a year ago.

Adjusted operating income was $9 million. Adjusted operating margin was 5.7%, an improvement of 60 basis points year over year.
- Adjusted gross margin was 46.7%, down 20 basis points year over year, reflecting higher costs and lower volumes in parts of the Multiomics segment, partially offset by continued cost discipline, operational improvements, and favorable sales mix in Sample Management Solutions.
- Adjusted operating expenses in the quarter were $65 million, up 4% year over year, primarily driven by higher selling, general and administrative expenses and higher research and development costs.
Adjusted EBITDA was $21 million, and Adjusted EBITDA margin was 13.0%, an improvement of 230 basis points year over year.
Non-GAAP Diluted EPS was $0.21, compared to $0.19 one year ago.

Revenue for fiscal 2025 was $594 million, up 4% year over year. Organic revenue increased 3%, which excludes the impact from foreign exchange. The year-over-year revenue increase was largely attributable to higher Multiomics revenue.
Sample Management Solutions revenue was $325 million, up 2% year over year.
- Organic revenue was up 1%, primarily driven by growth in Clinical Biostores, Consumables and Instruments and Sample Storage, partially offset by lower revenue in Cryogenic Systems and Automated Stores.
Multiomics revenue was $269 million, up 6% year over year.
- Organic revenue grew 5% year over year, driven by growth in Next Generation Sequencing, partially offset by a year-over-year revenue decline in Sanger sequencing and Gene Synthesis.

Operating loss was $27 million. Operating margin was (4.5%), an improvement of 440 basis points year over year.
- Gross margin was 45.5%, up 110 basis points year over year, primarily driven by higher revenue, favorable sales mix, operating efficiencies and improved cost execution.
- Operating expenses were $297 million, down 3% year over year due to lower research and development costs, lower selling, general and administrative expenses, lower restructuring charges, lower merger and acquisition costs and costs related to share repurchases, and lower amortization costs, as well as the impact of intangible asset impairment charges recorded in the prior year.
Other income included $19 million of net interest income versus $33 million in the prior year period.
Tax adjustments include a one-time $45.6 million benefit related to a worthless stock deduction on one of the Company's foreign subsidiaries.
Diluted EPS from continuing operations was $0.52 compared to ($0.46) in fiscal 2024. Diluted EPS from discontinued operations was ($1.81). Total diluted EPS was ($1.30), compared to ($3.10) a year ago.

Adjusted operating income was $16 million. Adjusted operating margin was 2.6%, an improvement of 200 basis points year over year.
- Adjusted gross margin was 46.9%, up 100 basis points year over year, primarily driven by favorable product mix, operating efficiencies and cost reduction initiatives.
- Adjusted operating expenses were $263 million, up 1% year over year, primarily driven by higher selling, general and administrative expenses, partially offset by lower research and development costs.
Adjusted EBITDA was $66 million, and Adjusted EBITDA margin was 11.2%, an improvement of 310 basis points year over year.
Non-GAAP Diluted EPS for fiscal 2025 was $0.51, compared to $0.48 in fiscal 2024.

The Company ended fiscal year 2025 with a total balance of cash, cash equivalents, restricted cash, and marketable securities of $546 million.
Capital expenditures were $8 million in the quarter and $34 million for the full year.

Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.
Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2025.